2013 American Society of Hematology Annual Meeting*

December 7-10, 2013; New Orleans, Louisiana
CCO’s Independent Conference Coverage of the 2013 American Society of Hematology annual meeting includes Capsule Summaries of key studies plus expert analyses of new clinical trial findings with downloadable highlights slidesets. Topics include chronic lymphocytic leukemia and other B-cell malignancies, chronic myeloid leukemia, myelodysplastic syndromes and acute leukemias, and multiple myeloma.

Chronic Myeloid Leukemia


Initial therapy with ponatinib in patients with chronic-phase CML yields high cytogenetic and molecular responses early in treatment but dose reductions due to toxicity were common.

Released: December 9, 2013

A nonsignificant trend was seen toward higher MMR rates with nilotinib vs imatinib in patients with a suboptimal response after 18-24 months of initial imatinib treatment.

Released: December 11, 2013

Reduction of BCR-ABL transcripts to 0.35 fold of baseline within 3 months on imatinib better predicted 5-year PFS and OS than 3-month BCR-ABLIS < 10%.

Released: December 12, 2013

BCR-ABL level reduction between 3 and 6 months on TKI therapy increased OS, PFS, and failure-free survival and achievement of major molecular response.

Released: December 11, 2013

Highly sensitive ultradeep sequencing–based screening identifies low-level TKI resistance mutations that can better inform second- or third-line therapy decisions.

Released: December 10, 2013

Patients show early and durable cytogenetic and hematologic responses as well as high rates of hypertension and increasing vascular occlusive events with longer treatment duration in the 2-year follow-up of the PACE trial.

Released: December 12, 2013

Dasatinib-treated patients show deeper molecular responses and fewer disease transformations compared with imatinib.

Released: December 11, 2013

Nilotinib shows increased rate of early molecular responses, which translates to improved survival and higher rates of MR4.5 at the 5-year follow-up.

Released: December 10, 2013

Dasatinib was associated with higher rates of molecular response than imatinib, but also higher rates of missed doses and treatment reductions.

Released: December 10, 2013

Although the primary endpoint of improved CCyR rate was not met, analyses of secondary endpoints accounting for treatment crossover suggest that switching to nilotinib may be associated with higher cytogenetic and molecular response rates than imatinib dose escalation.

Released: December 10, 2013
Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Educational grant provided by:
Celgene Corporation
Genentech BioOncology
Gilead Sciences
Takeda Oncology
Novartis Oncology
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?